361 related articles for article (PubMed ID: 34731857)
1. The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.
Wong MG; Lv J; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Reich HN; Cattran D; Glassock R; Levin A; Jardine MJ; Wheeler DC; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V;
Am J Nephrol; 2021; 52(10-11):827-836. PubMed ID: 34731857
[TBL] [Abstract][Full Text] [Related]
2. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Lv J; Zhang H; Wong MG; Jardine MJ; Hladunewich M; Jha V; Monaghan H; Zhao M; Barbour S; Reich H; Cattran D; Glassock R; Levin A; Wheeler D; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Wang HY; Perkovic V;
JAMA; 2017 Aug; 318(5):432-442. PubMed ID: 28763548
[TBL] [Abstract][Full Text] [Related]
3. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Lv J; Wong MG; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Jardine MJ; Reich HN; Cattran D; Glassock R; Levin A; Wheeler DC; Woodward M; Billot L; Stepien S; Rogers K; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V;
JAMA; 2022 May; 327(19):1888-1898. PubMed ID: 35579642
[TBL] [Abstract][Full Text] [Related]
4. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive agents for treating IgA nephropathy.
Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study.
Liang M; Xiong L; Li A; Zhou J; Huang Y; Huang M; Zhang X; Shi H; Su N; Wei Y; Jiang Z
BMC Nephrol; 2022 Jan; 23(1):40. PubMed ID: 35062886
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH; Barratt J; Heerspink HJL; Alpers CE; Bieler S; Chae DW; Diva UA; Floege J; Gesualdo L; Inrig JK; Kohan DE; Komers R; Kooienga LA; Lafayette R; Maes B; Małecki R; Mercer A; Noronha IL; Oh SW; Peh CA; Praga M; Preciado P; Radhakrishnan J; Rheault MN; Rote WE; Tang SCW; Tesar V; Trachtman H; Trimarchi H; Tumlin JA; Wong MG; Perkovic V;
Lancet; 2023 Dec; 402(10417):2077-2090. PubMed ID: 37931634
[TBL] [Abstract][Full Text] [Related]
8. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC; Barratt J; Cook H; Coppo R; Feehally J; de Fijter JW; Floege J; Hetzel G; Jardine AG; Locatelli F; Maes BD; Mercer A; Ortiz F; Praga M; Sørensen SS; Tesar V; Del Vecchio L;
Lancet; 2017 May; 389(10084):2117-2127. PubMed ID: 28363480
[TBL] [Abstract][Full Text] [Related]
9. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
Li P; Chen YZ; Lin HL; Ni ZH; Zhan YL; Wang R; Yang HT; Fang JA; Wang NS; Li WG; Sun XF; Chen XM
Trials; 2017 Apr; 18(1):170. PubMed ID: 28395659
[TBL] [Abstract][Full Text] [Related]
10. Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy: a prospective randomized controlled trial.
Liu H; Xu X; Fang Y; Ji J; Zhang X; Yuan M; Liu C; Ding X
Intern Med; 2014; 53(7):675-81. PubMed ID: 24694475
[TBL] [Abstract][Full Text] [Related]
11. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H
Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.
Hou FF; Xie D; Wang J; Xu X; Yang X; Ai J; Nie S; Liang M; Wang G; Jia N;
JAMA Netw Open; 2023 Feb; 6(2):e2254054. PubMed ID: 36745456
[TBL] [Abstract][Full Text] [Related]
13. Methylprednisolone pulse therapy combined with mizoribine following tonsillectomy for immunoglobulin A nephropathy: clinical remission rate, steroid sparing effect, and maintenance of renal function.
Kaneko T; Hirama A; Ueda K; Fujino T; Utsumi K; Iino Y; Katayama Y
Clin Exp Nephrol; 2011 Feb; 15(1):73-8. PubMed ID: 20972695
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R; Kristensen J; Stone A; Floege J; Tesař V; Trimarchi H; Zhang H; Eren N; Paliege A; Reich HN; Rovin BH; Barratt J;
Lancet; 2023 Sep; 402(10405):859-870. PubMed ID: 37591292
[TBL] [Abstract][Full Text] [Related]
15. Role of proteinuria reduction in the progression of IgA nephropathy.
Locatelli F; Pozzi C; Del Vecchio L; Bolasco PG; Fogazzi GB; Andrulli S; Melis P; Altieri P; Ponticelli C
Ren Fail; 2001; 23(3-4):495-505. PubMed ID: 11499564
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
Hou JH; Le WB; Chen N; Wang WM; Liu ZS; Liu D; Chen JH; Tian J; Fu P; Hu ZX; Zeng CH; Liang SS; Zhou ML; Zhang HT; Liu ZH
Am J Kidney Dis; 2017 Jun; 69(6):788-795. PubMed ID: 28215945
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroid for IgA Nephropathy: Are They Really Therapeutic?
Lin Y; Jia J; Guo Y; He D; Zhang Y; Wang F; Yan T; Liu Y; Lin S
Am J Nephrol; 2018; 47(6):385-394. PubMed ID: 29874651
[TBL] [Abstract][Full Text] [Related]
18. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H
Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
[TBL] [Abstract][Full Text] [Related]
19. Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: a 18-month prospective clinical trial.
Li Y; Fu R; Gao J; Wang L; Duan Z; Tian L; Ge H; Ma X; Zhang Y; Li K; Xu P; Tian X; Chen Z
Sci Rep; 2022 Jan; 12(1):255. PubMed ID: 34996948
[TBL] [Abstract][Full Text] [Related]
20. IGA nephropathy - Are intravenous steroid pulses more effective than oral steroids in relapse prevention?
Laranjinha I; Matias P; Cassis J; Branco P; Ramos S; Barata JD; Weigert A
Nefrologia (Engl Ed); 2018; 38(4):355-360. PubMed ID: 29129388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
